Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Inventory (2023 - 2025)

Historic Change in Inventory for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to $3.2 million.

  • Iovance Biotherapeutics' Change in Inventory fell 6773.15% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.7 million, marking a year-over-year decrease of 646.75%. This contributed to the annual value of $39.9 million for FY2024, which is 29451.47% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Change in Inventory is $3.2 million, which was down 6773.15% from -$6.9 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Change in Inventory registered a high of $14.5 million during Q4 2024, and its lowest value of -$6.9 million during Q2 2025.
  • For the 3-year period, Iovance Biotherapeutics' Change in Inventory averaged around $6.0 million, with its median value being $7.8 million (2024).
  • In the last 5 years, Iovance Biotherapeutics' Change in Inventory skyrocketed by 288559.32% in 2024 and then plummeted by 17836.1% in 2025.
  • Iovance Biotherapeutics' Change in Inventory (Quarter) stood at $923000.0 in 2023, then soared by 1466.85% to $14.5 million in 2024, then plummeted by 78.0% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, -$6.9 million for Q2 2025, and $14.0 million during Q1 2025.